The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD ...

AstraZeneca Pharma India Ltd has received approval from India's drug regulator to import and sell sodium zirconium ...

Lokelma is used for the treatment of hyperkalaemia, a condition characterized by elevated potassium levels in the blood.

NICE says that Lokelma can be used for non-dialysed patients with CKD or heart failure who have persistent hyperkalaemia with a potassium level of 6.0 mmol/litre or more that is preventing them ...

AstraZeneca Pharma India has received approval to import and sell sodium zirconium cyclosilicate (Lokelma) for treating hyperkalemia in adults in India. The drug is indicated for the treatment of ...

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...